IDEAYA Biosciences, Inc. (IDYA) SEC Filings & Earnings Calls

No product revenue, history of losses

“We do not have any products approved for sale and have not generated any product revenue since inception.” · word for word

Need for additional capital

“We anticipate that we will need to raise substantial additional capital.” · word for word

Clinical trial failure risk for other pipeline programs.

“Pipeline dependency on multiple trials; OS data immature.”

Substantial dilution from equity offering; may pressure stock price.

“Item 8.01: Issued 7.2M shares plus pre-funded warrants for 5.6M shares.”

Potential future dilution from ATM sales.

“Item 8.01: ATM prospectus supplement for up to $156.6M.”

Clinical trial failure risk

“We have incurred significant operating losses to date and expect that our operating expenses will increase significantly as we advance our product candidates through preclinical and clinical development.” · word for word

Partner dependency risk

“In December 2025, GSK notified us of its intention to terminate the GSK Collaboration Agreement, which became effective on March 9, 2026. We plan to discontinue development of IDE705 and are currently evaluating strategic options for this asset.” · word for word

Funding risk

“We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. Adequate additional funding may not be available to us on acceptable terms or at all.” · word for word

Regulatory approval risk

“We do not have any products approved for sale and have not generated any product revenue since inception.” · word for word

Clinical trial failure risk for other pipeline assets; regulatory approval not guaranteed.

“Multiple pipeline assets in early stages; OS data not yet mature; OptimUM-10 enrollment timeline revised.”

Early-stage clinical development; IDE849 is investigational with no approved products.

“The uncertainties inherent in early-stage clinical development; the risk that preclinical or clinical trial results may not be predictive of future results.” · word for word

Clinical trial risk for darovasertib topline results

“Topline PFS results expected late March 2026; if negative, could impact stock”

No approved products / clinical-stage only

“We currently have no products approved for commercial sale, have not generated any revenue from sales of products and have incurred losses in each year since our inception in June 2015.” · word for word

Substantial additional financing needed

“We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs.” · word for word

Clinical trial failure risk

“Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk.” · word for word

Clinical trial risks; results may not meet expectations.

“Topline results, including progression free survival (“PFS”) data, from ongoing registrational Phase 2/3 OptimUM-02 trial” · word for word

Dependence on pipeline success; no approved products yet.

“Darovasertib commercial readiness activities advancing” · word for word

Loss of GSK partnership; IDEAYA must now fund development alone

“GSK terminates collaboration; IDEAYA regains rights to IDE275 and IDE705”

Partner termination increases development risk and financial burden for IDE275 and IDE705.

“GSK terminated collaboration; IDEAYA must fund programs independently.”

No revenue, clinical-stage risk, pipeline dependency on trial outcomes

No approved products, history of losses

“We do not have any products approved for sale and have not generated any product revenue since inception.” · word for word

Future capital needs

“We anticipate that we will need to raise substantial additional capital, the requirements for which will depend on many factors.” · word for word